H-8 • 2HCl inhibits PKA (IC50=1.2μM) and cGKI (IC50=0.48μM) selectively over PKC (IC50=15μM) and MLCK (IC50=68μM). Experiments suggest that this compound selectively targets cyclic nucleotide dependent protein kinases. Mechanistic studies show that H-8 • 2HCl blocks signaling pathways in cellular regulations. More detailed results show that H-8 binds cyclin-dependent kinases at a T-loop region in a competitive manner and prevents downstream RNA synthesis of genes. H-8 • 2HCl is an inhibitor of Cdk7, Cdk8, cyclin C and cyclin H.
1. Hidaka, H., et al. 1984. Biochemistry. 23: 5036-5041. PMID: 6238627
2. Ido, M., et al. 1991. Br. J. Cancer. 64: 1103-1107. PMID: 1684908
3. Engh, R.A., et al. 1996. J. Biol. Chem. 271: 26157-26164. PMID: 8824261
4. Shima, D., et al. 2003. Genes Cells. 8: 215-223. PMID: 12622719
See how others have used H-8 dot 2HCL. Click on the entry to view the PubMed entry .
PMID: # 9841737 Light, DB. et al. 1998. J. Membr. Biol. 166: 119-132.
PMID: # 3574296 Hagiwara, M. et al. 1987. Mol. Pharmacol. 31: 523-528.
Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.